Merck and Ridgeback announced supply agreement with UNICEF for molnupiravir, investigational oral antiviral COVID-19 medicine
On Jan. 18, 2022, Merck and Ridgeback Biotherapeutics announced the signing of a long-term supply agreement with the…
On Jan. 18, 2022, Merck and Ridgeback Biotherapeutics announced the signing of a long-term supply agreement with the…
On Jan. 17, 2022, Our Future Health announced the launch of UKメs largest ever health research programme to…
On Jan. 16, 2022, the WHO announced that it had shipped 1.1 million COVID-19 vaccines to Rwanda on…
On Jan. 14, 2022, the WHO announced that it had recommended two new drugs for COVID-19, providing yet…
On Jan. 14, 2022, the U.S. Department of Agriculture’s (USDA) National Veterinary Services Laboratories confirmed a highly pathogenic…
On Jan. 14, 2022, the U.S. Department of Defense, in coordination with the U.S. Department of Health and…
On Jan. 13, 2022, the Centers for Disease Control and Prevention announced a study published in the journal…
On Jan. 13, 2022, OraSure Technologies that its InteliSwabᆴ COVID-19 rapid tests detected the Omicron variant as effectively…
On Jan. 12, 2022, Novavax and SK bioscience, a vaccine business subsidiary of Korea-based SK Group, announced that…
On Jan. 12, 2022, Pfizer announced positive top-line results from a Phase 3 study describing the safety and…
On Jan. 11, 2022, GlaxoSmithKline and Vir Biotechnology announced the US Government had purchased an additional 600,000 doses…
On Jan. 11, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration had expanded the…
On Jan. 10, 2022, Novavax and Serum Institute of India announced a regulatory submission to the South African…
On Jan. 10, 2022, in a first-of-its-kind surgery, a 57-year-old patient with terminal heart disease received a successful…
On Jan. 10, 2022, Novartis Molecular Partners announced that Part A of the EMPATHY clinical trial that compared…
On Jan. 10, 2022, the Biden-Harris Administration announced it was requiring insurance companies and group health plans to…
On Jan. 7, 2022, the Department of Defense, in coordination with the U.S. Department of Health and Human…
On Jan. 6, 2022, two new studies published in the journal Current Biology showed that environmental DNA (eDNA)…
On Jan. 5, 2022, Pfizer and BioNTech announced a new research, development and commercialization collaboration to develop a…
On Jan. 5, 2021, Humanigen announced that target enrollment in the Phase 2/3 ACTIV-5/BET-B study had been achieved….
On Jan 5, 2022, NRx Pharmaceuticals announced that it had submitted an application for Emergency Use Authorization (EUA)…
On Jan 5, 2022, Hologic the addition of the Aptimaᆴ SARS-CoV-2 assay to its Global Access Initiative, a…
On Jan 5, 2022, Revelar Biotherapeutics and Twist Bioscience announced that RBT-0813 binded to and neutralized the Omicron…
On Jan. 4, 2022, Tonix Pharmaceuticals announced an exclusive option agreement and research collaboration with Kansas State University…
On Jan. 4, 2022, Pfizer announced that the U.S. government had committed to purchasing an additional 10 million…
On Jan. 3, 2022, Amyris and ImmunityBio announced the completion of a previously announced joint venture agreement to…
On Jan. 3, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration had expanded the…
On Jan. 3, 2021, Humanigen announced that a manuscript detailing the results of an analysis of CRP levels…
On Dec. 30, 2021, Johnson & Johnson announced preliminary results from the South African Phase 3b Sisonke study…
On Dec. 29, 2021, the Department of Defense (DoD), on behalf of and in coordination with the U.S….